TABLE 2

First contingency description of the classification nomenclature for the marketed drugs screened for MDR1 transport and inhibition used within the manuscript

		In Vivo Observation
		Marketed for CNS Indication(s)	Marketed for Non-CNS Indication(s)
In Vitro Prediction	Permeates into brain (low ER, high P_appi)	True positive	False positive
In Vitro Prediction	Does not permeate into brain  (high ER, low P_appi)	False negative	True negative
	Total	P^{^a} = 76	N^{^b} = 90	S^{^c} = 166

↵^a Number of compounds marketed for CNS indications.
↵^b Number of compounds marketed for non-CNS indications.
↵^c Total number of compounds tested.